TrialClinical infectious diseases : an official publication of the Infectious Diseases Society of America2024

Twice-Daily Dolutegravir-Based Antiretroviral Therapy With 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis Prevention.

Anthony T Podany et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.